Cipla Limited (NSE: CIPLA, BSE: 500087) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,14,712 Cr, it ranks #103 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,391.80 (as of 16 Nov 2026), the share price is 9.6% below its 52-week high of ₹1,539.70 and 19.4% above its 52-week low of ₹1,165.70. The share price is down 7.6% over one year and down 4.6% over three months.
| Current Price | ₹1,391.80 |
|---|---|
| Market Cap | ₹1,14,712 Cr |
| NSE Symbol | CIPLA |
| BSE Code | 500087 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 29.3 |
| Return on Equity | 11.74% |
| Return on Assets | 7.58% |
| 52-Week Range | ₹1,165.70 – ₹1,539.70 |
| 1-Year Price Change | -7.6% |
| 3-Month Price Change | -4.6% |
| Beta (1Y) | -0.02 |
| Dividend Yield | 0.93% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.cipla.com |
| Revenue | ₹7,404 Cr |
|---|---|
| Net Profit | ₹852 Cr |
| Net Margin | 11.5% |
| EPS (Basic) | ₹10.86 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Cipla Limited reported revenue of ₹7,404 Cr in Q2 FY27, down 2.4% from ₹7,589 Cr in Q2 FY26 and up 4.0% from ₹7,119 Cr in Q1 FY27. It posted a net profit of ₹852 Cr for the quarter, against a net profit of ₹1,353 Cr in Q2 FY26 (down 37.1%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹6,541 Cr (Q4 FY26) to ₹7,589 Cr (Q2 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹7,404 Cr | ₹852 Cr | 11.5% |
| Q1 FY27 | ₹7,119 Cr | ₹786 Cr | 11.0% |
| Q4 FY26 | ₹6,541 Cr | ₹543 Cr | 8.3% |
| Q3 FY26 | ₹7,074 Cr | ₹674 Cr | 9.5% |
| Q2 FY26 | ₹7,589 Cr | ₹1,353 Cr | 17.8% |
| Q1 FY26 | ₹6,957 Cr | ₹1,292 Cr | 18.6% |
| Q4 FY25 | ₹6,730 Cr | ₹1,214 Cr | 18.0% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 29.21% of Cipla Limited's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 57.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
1. Pharmaceuticals-This segment develops, manufactures, sells, and distributes generic or branded generic medicines, as well as active pharmaceutical ingredients. 2. New Ventures-This segment engages in the consumer healthcare, biosimilars, and specialty businesses. 3. Inter Segment Revenue-0 4. Segment Adjustment-0
1. Pharmaceutical and Related Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Glenmark Pharmaceuticals Limited | ₹75,556 Cr | 55.1 | 14.07% | ₹4,157 Cr | +45.7% |
Listed by market capitalisation. Ratios are shown for context only.
Cipla Limited is trading at ₹1,391.80, with a market capitalisation of ₹1,14,712 Cr.
Cipla Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Cipla Limited has a P/E of 29.3 and a return on equity of 11.74%.
Cipla Limited is listed on the NSE under the symbol CIPLA and on the BSE under the scrip code 500087.
Cipla Limited's share price is down 7.6% over one year and down 4.6% over three months. Its 52-week range is ₹1,165.70 to ₹1,539.70.
In Q2 FY27, Cipla Limited reported revenue of ₹7,404 Cr and net profit of ₹852 Cr, with basic EPS of ₹10.86 (consolidated, parsed from the company's exchange filing).
Cipla Limited reported revenue of ₹7,404 Cr in Q2 FY27, down 2.4% from ₹7,589 Cr in Q2 FY26 and up 4.0% from ₹7,119 Cr in Q1 FY27.
Promoters held 29.21% of Cipla Limited's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.